<?xml version="1.0" encoding="UTF-8"?>
<p>Thus far, compulsory licensing – whether ending in an actual issuance or a lower negotiated drug price – has largely been for HIV/AIDS related treatments. In the 2000s, Brazil, Ecuador, Ghana, Indonesia, Malaysia, Mozambique, Thailand, Rwanda, Zambia, and Zimbabwe each issued compulsory licenses for one or more antiretroviral drugs to respond to the plight of their HIV-infected citizens who could not afford antiretroviral therapy. While most countries issued licenses for a specific patented drug, Ghana and Zimbabwe issued categorical compulsory licenses on all antiretroviral drugs [
 <xref rid="R7" ref-type="bibr">7</xref>].
</p>
